Nasdaq IPOs

As a rule, if March Madness gets canceled, then the IPO window is closed. Remarkably, one biotech pulled off an IPO this week, along with a blank check company. Outside of a few more SPACs, the IPO market may essentially shut down for months, as coronavirus fears reshape the 20

As a rule, if March Madness gets canceled, then the IPO window is closed. Remarkably, one biotech pulled off an IPO this week, along with a blank check company. Outside of a few more SPACs, the IPO market may essentially shut down for months, as coronavirus fears reshape the 20

Brilliant Acquisition, a blank check company targeting an Asia Pacific business, filed on Friday with the SEC to raise up to $40 million in an initial public offering.  The Shanghai, China-based company plans to raise $40 million by offering 4 million units at a price of $10

Brilliant Acquisition, a blank check company targeting an Asia Pacific business, filed on Friday with the SEC to raise up to $40 million in an initial public offering.  The Shanghai, China-based company plans to raise $40 million by offering 4 million units at a price of $10

Brilliant Acquisition, a blank check company targeting an Asia Pacific business, filed on Friday with the SEC to raise up to $40 million in an initial public offering.  The Shanghai, China-based company plans to raise $40 million by offering 4 million units at a price o

Brilliant Acquisition, a blank check company targeting an Asia Pacific business, filed on Friday with the SEC to raise up to $40 million in an initial public offering.  The Shanghai, China-based company plans to raise $40 million by offering 4 million units at a price o

Brilliant Acquisition, a blank check company targeting an Asia Pacific business, filed on Friday with the SEC to raise up to $40 million in an initial public offering.  The Shanghai, China-based company plans to raise $40 million by offering 4 million units at a price o

Since February 21, 2020, the S&P 500 has shed 18%, and the Renaissance IPO Index is down 17%. Of the 734 companies that have IPO'd over the past five years, 92% have traded down since the market sell-off began. A select few have bucked the trend.  While well-known v

Since February 21, 2020, the S&P 500 has shed 18%, and the Renaissance IPO Index is down 17%. Of the 734 companies that have IPO'd over the past five years, 92% have traded down since the market sell-off began. A select few have bucked the trend.  While well-known v

Since February 21, 2020, the S&P 500 has shed 18%, and the Renaissance IPO Index is down 17%. Of the 734 companies that have IPO'd over the past five years, 92% have traded down since the market sell-off began. A select few have bucked the trend.  Whi

Since February 21, 2020, the S&P 500 has shed 18%, and the Renaissance IPO Index is down 17%. Of the 734 companies that have IPO'd over the past five years, 92% have traded down since the market sell-off began. A select few have bucked the trend.  Whi

Since February 21, 2020, the S&P 500 has shed 18%, while the Renaissance IPO Index is down 17%. Of all 734 active IPOs since 2015, just 36% are trading above issue, and only 8% have positive returns since late February. Of these IPOs, the top performers are mainly bio

Imara, a Phase 2 biotech developing small molecule therapies for rare genetic disorders, raised $75 million by offering 4.7 million shares at $16, the low end of the range of $16 to $18, to command a $286 million fully diluted market cap. Imara plans to list on the Nasdaq under t

Imara, a Phase 2 biotech developing small molecule therapies for rare genetic disorders, raised $75 million by offering 4.7 million shares at $16, the low end of the range of $16 to $18, to command a $286 million fully diluted market cap. Imara plans to list on the Nasdaq under

Imara, a Phase 2 biotech developing small molecule therapies for rare genetic disorders, raised $75 million by offering 4.7 million shares at $16, the low end of the range of $16 to $18, to command a $286 million fully diluted market cap. Imara plans to list on the Nasdaq under

Imara, a Phase 2 biotech developing small molecule therapies for rare genetic disorders, raised $71 million by offering 4.5 million shares at $16, the low end of the range of $16 to $18, to command a $283 million fully diluted market cap. Imara plans to list on the Nasdaq under